CNS Pharmaceuticals (NASDAQ:CNSP) Trading Up 6.5% – Here’s Why

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)’s stock price rose 6.5% during trading on Wednesday . The company traded as high as $0.12 and last traded at $0.12. Approximately 13,369,292 shares traded hands during mid-day trading, an increase of 139% from the average daily volume of 5,602,099 shares. The stock had previously closed at $0.11.

Analyst Ratings Changes

Separately, Maxim Group upgraded shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Tuesday, September 10th.

CNS Pharmaceuticals Trading Up 6.5 %

The company has a market capitalization of $6.92 million, a PE ratio of 0.00 and a beta of 2.55. The firm has a 50 day simple moving average of $0.12 and a two-hundred day simple moving average of $0.42.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.